☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

☑ Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

OMB APPROVAL OMB Number: 3235-0287

Estimated average burden hours per response... 0.5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *				2. Issuer Name and Ticker or Trading Symbol						5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
PETERS WILLIAM J				Amphastar Pharmaceuticals, Inc. [AMPH]							_X_ Director		10%	6 Owner	
(Last) (First) (Middle)				3. Date of Earliest Transaction (MM/DD/YYYY)							X_ Officer (give title below) Other (specify below) CFO, EVP & Treasurer				
EUTICA	LS, INC.	, 11570				11/1	14/2	2023							
(Stre	eet)		4.	If An	nendm	ent, Date C)rig	inal Fil	ed (MM/I	DD/YYYY)	6. Individual o	or Joint/G	roup Filing	(Check Appl	icable Line)
		A 91730												'erson	
City) (Sta	te) (Zıp)														
	Т	able I - N	on-De	rivati	ive Se	curities Ac	qui	red, Di	isposed	of, or Ben	eficially Owne	d			
1. Title of Security (Instr. 3)		2. Trans		Execut	ion	3. Trans. Cod (Instr. 8)	str. 8)		4. Securities Acquired (A) Disposed of (D) (Instr. 3, 4 and 5)		following Reported Transaction(s) Ownership Form: Direct (D) Ownership of Ind Benef Ownership Ownership of Ind Ownership Own			Beneficial Ownership	
						Code	V	Amount	(A) or (D)	Price				or Indirect (I) (Instr. 4)	(Instr. 4)
Common Stock 11/14/2			/2023			M		21,250	A	\$20.23			122,610	D	
Common Stock 11/14/2			2023			M		38,000	A	\$13.03			160,610	D	
Common Stock 11/14/2023			2023	3		S(1)		14,220	D	\$54.7626 ⁽²⁾			146,390	D	
Common Stock 11/14/2023			2023	$\mathbf{s}^{(\underline{1})}$		$s^{(1)}$		30,162	D g	\$55.6728 ⁽³⁾		116,228		D	
Common Stock 11/14/2023			2023			S ⁽¹⁾		14,868	D	\$56.534 ⁽⁴⁾			101,360	D	
Tab	le II - Deriv	ative Sec	urities	Bene	eficiall	y Owned (arrants, o	ptions, conver	tible secu			
2. Conversion or Exercise Price of Derivative Security	Date	3A. Deemed Execution Date, if any	Code	ode		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		Securities Derivative	Underlying Security		derivative Securities Beneficially Owned	Security:	11. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	(A)	(D)				Title	Amount or Number of Shares		Reported	or Indirect	
\$20.23	11/14/2023		M			21,250		<u>(5)</u>	3/15/2029	Commor Stock	21,250	\$0	15,225	D	
\$13.03	11/14/2023		М			38,000		<u>(5)</u>	3/16/2030	Commor Stock	38,000	\$0	31,100	D	
	(First ASTAR EUTICA T (Stre CUCAMC City) (Sta Tab 2. Conversion or Exercise Price of Derivative Security	Table II - Deriv 2. Conversion or Exercise Price of Derivative Security (S20.23 11/14/2023	(First)	ILLIAM J A A A A A A A A A	Amphample Amphample Amphample Amphample Astar	Amphasta AMPH 3. Date of Earl 3. Date of Earl 3. Date of Earl 3. Date of Earl 4. If Amendm 5. UCAMONGA, CA 91730 5. European 5. European	Amphastar Pharm AMPH	Amphastar Pharmace AMPH	Amphastar Pharmaceutica AMPH	Amphastar Pharmaceuticals, Inc.	Amphastar Pharmaceuticals, Inc. AMPH	Amphastar Pharmaceuticals, Inc.	Amphastar Pharmaceuticals, Inc.	Amphastar Pharmaceuticals, Inc. [AMPH	Check all applicable Amphastar Pharmaceuticals, Inc. AMPH

Explanation of Responses:

- (1) The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 5, 2023.
- (2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$54.15 to \$55.145, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form
- (3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$55.16 to \$56.15, inclusive.

- (4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$56.17 to \$56.81, inclusive.
- (5) Shares subject to the option are fully vested and immediately exercisable.

Reporting Owners

Panarting Overar Nama / Address	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
PETERS WILLIAM J C/O AMPHASTAR PHARMACEUTICALS, INC. 11570 6TH STREET RANCHO CUCAMONGA, CA 91730	X		CFO, EVP & Treasurer			

Signatures

/s/ William J Peters	11/16/2023
**Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.